GSE216540 fulvestrant 10 v 6 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE216540_fulvestrant_10_v_6_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE216540_fulvestrant_10_v_6_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE216540_fulvestrant_10_v_6_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE216540_fulvestrant_10_v_6_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

small nucleolar RNA host gene 5

Gene

general transcription factor IIi pseudogene 4

Gene

leukocyte receptor cluster member 9

Gene

ribosomal protein S2 pseudogene 5

Gene

HLA complex group 11

Gene

glucosylceramidase beta 1 like, pseudogene

Gene

ALDH1A3 antisense RNA 1

Gene

WAP four-disulfide core domain 21, pseudogene

Gene

CYP1B1 antisense RNA 1

Gene

uncharacterized LOC100506076

  • Gene

    small nucleolar RNA host gene 5


  • Gene

    general transcription factor IIi pseudogene 4


  • Gene

    leukocyte receptor cluster member 9


  • Gene

    ribosomal protein S2 pseudogene 5


  • Gene

    HLA complex group 11


  • Gene

    glucosylceramidase beta 1 like, pseudogene


  • Gene

    ALDH1A3 antisense RNA 1


  • Gene

    WAP four-disulfide core domain 21, pseudogene


  • Gene

    CYP1B1 antisense RNA 1


  • Gene

    uncharacterized LOC100506076

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.